Advertisement

Strahlentherapie und Onkologie

, Volume 174, Issue 9, pp 449–456 | Cite as

Endokrine Orbitopathie: Vergleich der Langzeitergebnisse und Klassifikationen nach Radiotherapie

  • M. Heinrich Seegenschmiedt
  • Ludwig Keilholz
  • Gabriele Gusek-Schneider
  • Stefan Barth
  • Johannes Hensen
  • Friedrich Wolf
  • Gottfried O. H. Naumann
  • Rolf Sauer
Aktuelles Forum

Zusammenfassung

Hintergrund

Diese Studie vergleicht vier verschiedene Klassifikationen bei Patienten mit fortgeschrittener, therapierefraktärer endokriner Orbitopathie und untersucht deren prognostische Wertigkeit.

Patienten und Methode

Von 1984 bis 1994 wurden 60 konsekutive Patienten (49 Frauen, elf Männer) wegen progredienter, therapierefraktärer endokriner Orbitopathie bestrahlt (Linac 6 MV, 10mal 2 Gy). Im Verlauf wurden die Symptome und funktionellen Einschränkungen nach vier Klassifikationen bewertet: Werner-Score, modifizierter ATA-Score, Standford-Score und Ophthalmopathieindex (OI) nach Grussendorf [26, 27]. Außerdem notierten alle Patienten das subjektive Ansprechen auf einer linearen Skala (0 bis 100%).

Ergebnisse

Im Verlauf eines Jahres nach Radiotherapie besserten sich der Werner-Score bei 28 (47%) Patienten um ≥1 Kategorie, nach modifizierten ATA-Score 48 (80%), nach Stanford-Score 47 (78%) und nach OI-Score 55 (92%) Patienten (Reduktion um >2 Punkte). Der Werner-Score korrelierte kaum mit den anderen Scores (Koeffizient r<0,5), während diese untereinander hoch korrelierten (r ∼0,9). Der modifizierte ATA-Score besserte sich in den einzelnen Symptomkategorien zwischen 47% (Stadium VI) und 87% (Stadium V). Der OI-Score reduzierte sich im Mittel um sechs Punkte. Das subjektive Befinden besserte sich um +70±25%. Akute oder chronische Nebenwirkungen traten nicht auf. In multivariater Analyse waren das „männliches Geschlecht” (p=0,08)., die „Symptomdauer vor Radiotherapie >1 Jahr” (p=0,14) und die „hohe Symptomkategorie” (p=0,11) tendenziell negative Prognosefaktoren.

Schlußfolgerung

Die Radiotherapie ist auch bei schwerer progredienter endokriner Orbitopathie effektiv. Zur Bewertung sind mindestens zwölf Monate Nachbeobachtung und einheitliche Bewertungskriterien erforderlich.

Schlüsselwörter

Endokrine Orbitopathie Benigne Erkrankung Radiotherapie Klassifikation Qualitätssicherung 

Long-Term results and comparison of classifications after radiotherapy for graves orbitopathy

Abstract

Background

This study compares 4 classifications in patients with progressive refractory Graves orbitopathy (GO) and examines their prognostic value in long-term follow-up.

Patients and Methods

From 1984 to 1994, 60 consecutive patients (49 female, 11 male) received 20 Gy (10×2 Gy) radiotherapy with 6 MV Linac photons. Ocular symptoms and functional impairment was evaluated according to 4 GO-classification systems: Werner-, modified ATA- and Stanford-Score and Ophthalmopathy-Index (OI) according to Grussendorf [26, 27]. In addition, all patients noted their subjective response on a linear scale (0 to 100%).

Results

Improvement was achieved within 1 year after radiotherapy according to the Werner-Score in 28 (47%) patients in ≥1 symptom category, according to the modified ATA-score in 48 (80%), the Stanford-score in 47 (78%) and the OI-Score in 55 (92%) patients (reduction of >2 points). The Werner-Score correlated less to the other scores (coeffizient r<0.5) than the other scores among themselves (r ∼0.9). The ATA-Score improved in the different symptom categories between 47% (stage VI) and 87% (stage V). The OI-Score was reduced by a mean of 6 points. The patients reached a mean subjective improvement of +70±25%. Acute or chronic side effects were not observed. In multivariate analysis the “male gender” (p=0.08), a “symptom duration prior to radiotherapy >1 year” (p=0.14) and a “high symptom category” (p=0.11) indicated a negative prognostic trend.

Conclusions

External radiotherapy is effective for severe, progressive GO after pretreatment. A minimum follow-up of at least 12 months and standardized classification and success criteria are required.

Key Words

Graves’ orbitopathy Benign diseases Radiotherapy Classification Quality assurance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anonymus. Classification of eye changes of Graves’ disease. Thyroid 1992;2:235–6.Google Scholar
  2. 2.
    Appelqvist P, Salmo M, Rissanen P. Radiotherapy in emergency treatment of malignant exophthalmus. Strahlenther Onkol 1990;166:190–3.PubMedGoogle Scholar
  3. 3.
    American Thyroid Association. Classification of eye changes of Graves’ disease. Thyroid 1992;2:235–6.CrossRefGoogle Scholar
  4. 4.
    Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983;56:1139–44.PubMedGoogle Scholar
  5. 5.
    Bartalena L, Martino E, Marcocci C, et al. More on smoking habits and Graves’ ophthalmopathy. J Endocrinol Invest 1989;12:733–7.PubMedGoogle Scholar
  6. 6.
    Bartalena L, Marcocci C, Panicucci M, et al. Orbital irradiation in the treatment of Graves’ ophthalmopathy. Bull Soc Belge Ophthalmol 1988;226:71–83.Google Scholar
  7. 7.
    Boergen K. Surgical repair of motility impairment in Graves’ orbitopathy. Dev Ophthalmol 1989;20:159–68.PubMedGoogle Scholar
  8. 8.
    Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992;304:1343–6.CrossRefGoogle Scholar
  9. 9.
    Brennan MW, Leone CR, Janaki L. Radiation therapy for Graves’ disease. Am J Ophthalmol 1983;96:195–9.PubMedGoogle Scholar
  10. 10.
    Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Rev 1993;146:747–93.Google Scholar
  11. 11.
    DeGroot LJ, Gorman CA, Pinchera A, et al. Therapeutic controversies. Radiation and Graves’ ophthalmopathy. J Clin Endocrinol Metab 1995;80:339–49.PubMedCrossRefGoogle Scholar
  12. 12.
    Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 1973;37:276–85.PubMedGoogle Scholar
  13. 13.
    van Dijk HJL. Orbital Graves’ disease: a modification of the “no specs” classification. Opthalmology 1981;88:479–83.Google Scholar
  14. 14.
    Erickson BA, Harris GJ, Lewandowski MF, et al. Echographic monitoring of response of extraocular muscles to irradiation in Graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys 1995;31:651–60.PubMedGoogle Scholar
  15. 15.
    Esser J. Endokrine Orbitopathie. Chirurgische Eingriffe an den äußeren Augenmuskeln. Ophthalmologe 1994;91:3–19.PubMedGoogle Scholar
  16. 16.
    Esser J, Molls M, Benker G. Quantitative Ergebnisse nach konsekutiver Corticoid- und Radiotherapie bei endokriner Ophthalmopathie. Fortschr Ophthalmol 1988;85:323–6.PubMedGoogle Scholar
  17. 17.
    Esser J, Sauerwein W, Olbricht T. Corticoid- und Strahlentherapie bei endokriner Orbitopathie. Nuklearmediziner 1995;18:163–77.Google Scholar
  18. 18.
    Feldon SE, Unsöld R. Graves’ ophthalmopathy evaluated by infrared eye-movement recordings. Arch Ophthalmol 1982;100:324–8.PubMedGoogle Scholar
  19. 19.
    Feyerabend T, Richter E, Buschmann W, et al. Die Rolle der Strahlentherapie bei der endokrinen Orbitopathie. Klin Mbl Augenheilk 1989;195:1–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Friedrich A, Kamprad F, Goldmann A. Clinical importance of radiotherapy in the treatment of Graves’ disease. In: Wiegel T, Bornfeld N. Foerster MH, et al. eds. Radiotherapy of ocular disease. Front Radiat Ther Oncol 1997;30:206–17.Google Scholar
  21. 21.
    Fritsch R, Hassenstein E, Dausch D. Ergebnisse der Retrobulbärbestrahlung bei benigner endokriner Ophthalmopathie. Strahlentherapie 1981;157:305–9.PubMedGoogle Scholar
  22. 22.
    Garrity JA, Bartley GB, DeSanto LW, et al. Orbital compression. Longterm results. In: Wall JR, How J, eds. Graves’ ophthalmopathy. Cambridge, MA: Blackwell, 1990:171–82.Google Scholar
  23. 23.
    Gerling J, Jung E, Kommerell G. Retrobulbärbestrahlung bei endokriner Orbitopathie: Literaturübersicht und Ansatz für eine prospektive Studie. Z Prakt Augenheilk 1993;14:265–72.Google Scholar
  24. 24.
    Given-Wilson R, Pope R, Michell MJ, et al. The use of real-time orbital ultrasound in Graves’ ophthalmopathy: A comparison with computed tomography. Br J Radiol 1989;62:705–9.PubMedGoogle Scholar
  25. 25.
    Grauthoff H, Wuttke H, Frommhold H. Zur Strahlentherapie der endokrinen Orbitopathie. Strahlentherapie 1980;156:226–34.Google Scholar
  26. 26.
    Grussendorf M, Nowoczyn V, Horster FA, et al. Standardisierung und Auswertung klinischer Befunden bei Patienten mit endokriner Ophthalmopathie. Aktuel Endokrinol 1988;9:35–44.Google Scholar
  27. 27.
    Grussendorf M, Nowoczyn V, Horster FA, et al. Standardization and evaluation of clinical findings in patients suffering from Graves’ ophthalmopathy. In: Pickardt CR, Boergen KP. Graves’ ophthalmopathy, developments in diagnostic methods and therapeutical procedures. Dev Ophthalmol 1989;20:8–12.Google Scholar
  28. 28.
    Hallin ES, Feldon SE. Graves’ ophthalmopathy: I. Simple CT estimates of extraocular muscle volume. Br J Ophthalmol 1988;72:674–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Hallin ES, Feldon SE. Graves’ ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography. Br J Ophthalmol 1988;72:678–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Harner SG. Orbital decompression techniques. In: Gorman CA, Cambell RJ, Dyer JA, eds. The eye and orbit in thyroid disease. New York: Raven Press, 1984:221–30.Google Scholar
  31. 31.
    Heinze HG, Pickardt CR, Brand H. Strahlentherapie der endokrinen Ophthalmopathie mit 18 MeV-Bremsstrahlung. Strahlentherapie 1974; 148:226–34.PubMedGoogle Scholar
  32. 32.
    Heufelder AE, Schworm HD, Hofbauer LC. Die endokrine Orbitopathie: Aktueller Stand zur Pathogenese, Diagnostik und Therapie. Dtsch Ärztebl 1996;93:1043–9.Google Scholar
  33. 33.
    Holt JE, O’Connor PS, Douglas JP, et al. Extraocular muscle size comparison using standardized A-scan echography and computed tomography scan measurements. Ophthalmology 1985;92:1351–5.PubMedGoogle Scholar
  34. 34.
    Horst W, Glanzmann C. Diagnostik und Therapie der endokrinen Ophthalmopathie. Therapiewoche 1982;32:4848–55.Google Scholar
  35. 35.
    Horster FA, Wildmeister W. Endokrine Orbitopathie. Dtsch Med Wochenschr 1983;108:413–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Hurbli T, Char DH, Harris J, et al. Radiation therapy for thyroid eye diseases. Am J Ophthalmol 1985;99:633–7.PubMedGoogle Scholar
  37. 37.
    Jacobsen DH, Gorman CA. Diagnosis and management of endocrine ophthalmopathy. Med Clin North Am 1985;69:973–88.Google Scholar
  38. 38.
    Jones A. Orbital x-ray therapy of progressive exophthalmus. Br J Radiol 1951;24:637–46.PubMedGoogle Scholar
  39. 39.
    Kahaly G, Stover C, Otto E, et al. Glycosaminoglycans in thyroid associated ophthalmopathy. Autoimmunity 1992;13:81–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kahaly G, Hansen C, Felke B, et al. Immunohistochemical staining of retrobulbar adipose tissue in Graves’ ophthalmopathy. Clin Immunol Immunopathol 1994;73:53–62.PubMedCrossRefGoogle Scholar
  41. 41.
    Kahaly G, Förster G, Pitz S, et al. Aktuelle interdisziplinäre Diagnostik und Therapie der endokrinen Orbitopathie. Dtsch Med Wochenschr 1997;122:27–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Kao SCS, Kendler DL, Nugent RA, et al. Radiotherapy in the management of thyroid orbitopathy. Computed tomography and outcomes. Arch Ophthalmol 1993;111:819–23.PubMedGoogle Scholar
  43. 43.
    Kazim M, Trokel S, Moore S. Treatment of acute Graves’ orbitopathy. Ophthalmology 1991;98:1443:8.PubMedGoogle Scholar
  44. 44.
    Kennerdell JS. Orbital decompression: an overview. In: Wall JR, How J, eds. Graves’ ophthalmopathy. Cambridge, MA: Blackwell, 1990:159–70.Google Scholar
  45. 45.
    Kinyoun JL, Orcutt JC. Radiation retinopathy. JAMA 1987;258:610–1.PubMedCrossRefGoogle Scholar
  46. 46.
    Konishi J, Iida Y, Kasagi K, et al. Clinical evaluation of radiotherapy for Graves’ ophthalmopathy. Endocrinol Jpn 1986;33:637–44.PubMedGoogle Scholar
  47. 47.
    Kriss JP, McDougall IR, Donaldson SS. Graves’ ophthalmopathy. In: Krieger DT, Bardin WC, eds. Current therapy in endocrinology 1983–84. Toronto: Becker-Mosby, 1983:104–9.Google Scholar
  48. 48.
    Kriss JP, McDougall IR, Donaldson SS, et al. Non-thyroidal complications of Graves’ disease: perspective on pathogenesis and treatment. In: Pinchera A, Ingbar S, McKenzie J, et al., eds. Thyroid autoimmunity. Pisa: Plenum Press, 1987:263–9.Google Scholar
  49. 49.
    Kriss JP, Petersen IA, Donaldson SS, et al. Supervoltage orbital radiotherapy for progressive Graves’ ophthalmopathy: results of a twenty year experience. Acta Endocrinol (Copenh) 1989;121:154–9.Google Scholar
  50. 50.
    van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994;12:312–25.PubMedGoogle Scholar
  51. 51.
    Lloyd WC, Leone CR. Supervoltage orbital radiotherapy in 36 cases of Graves’ disease. Am J Ophthalmol 1992;113:374–80.PubMedGoogle Scholar
  52. 52.
    Marcocci C, Bartalena L, Panicucci M, et al. Orbital cobalt irradiation combined with retrobulbar or systematic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin Endocrinol 1987;27:33–42.CrossRefGoogle Scholar
  53. 53.
    Marcocci C, Bartalena L, Bogazzi F, et al. Role of orbital radiotherapy in the treatment of Graves’ ophthalmopathy. Exp Clin Endocrinol 1991;97:332–7.PubMedGoogle Scholar
  54. 54.
    Marcocci C, Bartalena L, Bruno-Bossio G, et al. Orbital radiotherapy of endocrine ophthalmopathy. Why and when. In: Kahaly G, ed. Endocrine ophthalmopathy. Molecular, immunological and clinical aspects. Basel: Karger, 1993:131–41.Google Scholar
  55. 55.
    Miller ML, Goldberg SH, Bullock JD. Radiation retinopathy after standard radiotherapy for thyroid-related opthalmopathy. Am J Ophthalmol 1991;112:600–1.PubMedGoogle Scholar
  56. 56.
    Mourits M, Koornneef L, Wiersinga W, et al. Orbital decompression for Graves’ ophthalmopathy by inferomedial plus lateral and coronal approach. Ophthalmology 1990;97:636–41.PubMedGoogle Scholar
  57. 57.
    Nugent RA, Belkin RI, Neigel JM, et al. Graves’ orbitopathy: Correlation of CT and clinical findings. Radiology 1990;177:675–82.PubMedGoogle Scholar
  58. 58.
    Olivotto IA, Ludgate CM, Allen LH, et al. Supervoltage radiotherapy for Graves’ ophthalmopathy: CCABC technique and results. Int J Radiat Oncol Biol Phys 1985;11:2085–90.PubMedGoogle Scholar
  59. 59.
    Order S, Donaldson S. Radiation therapy of benign diseases. Berlin-Heidelberg-New York: Springer 1990.Google Scholar
  60. 60.
    Otto E, Ochs K, Hansen C, et al. Orbital tissue-derived T-lymphocytes from patients with Graves’ orbitopathy recognize autologous orbital antigenes. J Clin Endocrinol Metab 1996;80:3045–50.CrossRefGoogle Scholar
  61. 61.
    van Ouwerkerk BM, Wijngaarde R, Hennemann G, et al. Radiotherapy of severe ophthalmic Graves’ disease. J Endocrinol Invest 1985;8:241–7.PubMedGoogle Scholar
  62. 62.
    Palmer D, Greenberg P, Cornell P, et al. Radiation therapy for Graves’ ophthalmopathy: a retrospective analysis. Int J Radiat Oncol Biol Phys 1987;13:1815–20.PubMedGoogle Scholar
  63. 63.
    Parker RG, Withers HR. Radiation retinopathy. JAMA 1988;259:43–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Pascke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves’ disease and thyroid associated opthalmopathy. Clin Endocrinol 1995;42:565–9.CrossRefGoogle Scholar
  65. 65.
    Petersen IA, Donaldson SS, McDougall IR, et al. Prognostic factors in the radiotherapy of Graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys 1990;19:259–64.PubMedGoogle Scholar
  66. 66.
    Pfluger T, Wendt T, Toroutoglou N, et al. Retrobulbärbestrahlung bei endokriner Ophthalmopathie: Vergleich zwischen 10 und 16 Gy Herddosis. Strahlenther Onkol 1990;166:673–7.PubMedGoogle Scholar
  67. 67.
    Pigeon P, Orgiazzi J, Berthezene F, et al. High voltage orbital radiotherapy and surgical orbital decompression in the management of Graves’ ophthalmopathy. Horm Res 1987;26:172–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Prummel MF, Mourits M, Blank L, et al. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 1993;342:949–54.PubMedCrossRefGoogle Scholar
  69. 69.
    Ravin JG, Sisson JC, Knapp WT. Orbital radiation for the ocular changes of Graves’ disease. Am J Ophthalmol 1975;79:285–8.PubMedGoogle Scholar
  70. 70.
    Sandler HM, Rubenstein JH, Fowble BL, et al. Results of radiotherapy for thyroid ophthalmopathy. Int J Radiat Oncol Biol Phys 1989;17:823–7.PubMedGoogle Scholar
  71. 71.
    Seegenschmiedt MH, Becker W, Gusek G, et al. Megavoltage radiotherapy for severe and refractory progressive Graves’ ophthalmopathy: comparison of scoring systems and long-term results. Int J Radiat Oncol Biol Phys 1995;32:Suppl:286.CrossRefGoogle Scholar
  72. 72.
    Shah KJ, Dasher BG, Brooks B. Computed tomography of Graves’ ophthalmopathy, diagnosis, management, and posttherapeutic evaluation. Clin Imaging 1989;13:58–61.PubMedCrossRefGoogle Scholar
  73. 73.
    Shine B, Fells P, Edwards OM, et al. Association between Graves’ ophthalmopathy and smoking. Lancet 1990;335:1261–3.PubMedCrossRefGoogle Scholar
  74. 74.
    Snijders-Keilholz A, De Keizer RJW, Goslings BM, et al. Probable risk of tumour induction after retroorbital irradiation for Graves’ ophthalmopathy. Radiother Oncol 1996;38:69–71.PubMedCrossRefGoogle Scholar
  75. 75.
    Staar S, Müller R-P, Hammer M, et al. Results and prognostic factors in retrobulbar radiotherapy combined with systemic corticosteroids for endocrine orbitopathy (Graves’ disease). In: Wiegel T. Bornfeld N, Foerster M, et al., eds. Radiotherapy of ocular disease. Front Radiat Ther Oncol 1997;30:206–17.Google Scholar
  76. 76.
    Teng CS, Crombie AL, Hall R, et al. An evaluation of supervoltage orbital irradiation for Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1980;13:545–51.CrossRefGoogle Scholar
  77. 77.
    Uhlenbrock D, Fischer HJ, Rohwerder R. Strahlentherapie der endokrinen Ophthalmopathie — Auswertung von 56 Fällen. Strahlentherapie 1984;160:485–91.PubMedGoogle Scholar
  78. 78.
    Volpe R. Graves’ hyperthyroidism and endocrine ophthalmopathy. One or two closely related diseases. In: Kahaly G, ed. Endocrine opthalmopathy, molecular, immunological and clinical aspects. Basel: Karger, 1993:101–11.Google Scholar
  79. 79.
    Werner S. Classification of the eye change of Graves’ disease. J Clin Endocrinol Metab 1969;29:982–4.PubMedGoogle Scholar
  80. 80.
    Werner SC. Modification of the classification of the eye change of Graves’ disease: recommendations of the Ad Hoc Committee of the American Thyroid Association: J Clin Endocrinol Metab 1977;44:203–4.PubMedCrossRefGoogle Scholar
  81. 81.
    Wildmeister W, Horster FA. Zur Therapie der endokrinen Ophthalmopathie. Dtsch Med Wochenschr 1972;97:1708–11.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 1998

Authors and Affiliations

  • M. Heinrich Seegenschmiedt
    • 5
  • Ludwig Keilholz
    • 1
  • Gabriele Gusek-Schneider
    • 2
  • Stefan Barth
    • 1
  • Johannes Hensen
    • 3
  • Friedrich Wolf
    • 4
  • Gottfried O. H. Naumann
    • 2
  • Rolf Sauer
    • 1
  1. 1.Klinik für Strahlentherapie der Universität Erlangen-NürnbergErlangen-NürnbergDeutschland
  2. 2.Augenklinik mit Poliklinik der Universität Erlangen-NürnbergErlangen-NürnbergDeutschland
  3. 3.Medizinische Klinik I (Abteilung Endokrinologie) mit Poliklinik der Universität Erlangen-NürnbergErlangen-NürnbergDeutschland
  4. 4.Nuklearmedizinische Klinik der Universität Erlangen-NürnbergErlangen-NürnbergDeutschland
  5. 5.Klinik für Radioonkologie, Strahlentherapie und NuklearmedizinAlfried-Krupp-Krankenhaus EssenEssen

Personalised recommendations